Article Figures & Data
- Supplementary Figures S1 and S2: Association of MRD with survival outcomes in myeloma patients - 1) Munshi Figures, 2) MRD Negativity Associated With Longer Progression-free Survival And Overall Survival In Newly Diagnosed Multiple Myeloma Patients
- Supplementary Table S1: IMWG Criteria for MRD negativity - Adapted from: Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-46.
- Supplementary Table S2: Clinical trials in myeloma using MRD assessments - Active Clinical Trials in Myeloma Using Minimal Residual Disease Assessment as Exploratory or Secondary Endpoints